Docoh
Loading...

ANGN Angion Biomedica

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Tuesday
18 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Tuesday morning saw 454 companies set new 52-week lows.
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
5 Jan 22
Biotech, News, Penny Stocks, Guidance, Financing, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
63 Biggest Movers From Yesterday
31 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
44 Stocks Moving In Thursday's Mid-Day Session
30 Dec 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
50 Biggest Movers From Friday
13 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers SigmaTron International, Inc. (NASDAQ: SGMA) jumped 84.7% to settle at $14.94 on Friday after the company reported Q2 EPS and sales results were higher year over year.
Mid-Afternoon Market Update: Dow Rises 150 Points; SigmaTron International Shares Spike Higher
10 Dec 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Global, Intraday Update, Markets
Toward the end of trading Friday, the Dow traded up 0.42% to 35,905.44 while the NASDAQ rose 0.34% to 15,570.02. The S&P also rose, gaining 0.66% to 4,698.21.
36 Stocks Moving In Friday's Mid-Day Session
10 Dec 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
Mid-Day Market Update: Oracle Gains Following Upbeat Q2 Results; Angion Biomedica Shares Drop
10 Dec 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Global, Intraday Update, Markets
Midway through trading Friday, the Dow traded up 0.09% to 35,787.47 while the NASDAQ rose 0.34% to 15,570.02. The S&P also rose, gaining 0.38% to 4,685.15.
Mid-Morning Market Update: Markets Open Higher; Inflation Rate Increases To 6.8%
10 Dec 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Global, Intraday Update, Markets
Following the market opening Friday, the Dow traded up 0.48% to 35,924.79 while the NASDAQ rose 0.47% to 15,579.93. The S&P also rose, gaining 0.60% to 4,695.55.
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
10 Dec 21
Biotech, Earnings, News, Penny Stocks, Small Cap, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Angion's ANG-3777 Faces Third Failure In 2021, This Time Flunks Acute Kidney Injury Trial
10 Dec 21
Biotech, News, Penny Stocks, Short Ideas, Health Care, Movers, Trading Ideas, General
Angion Biomedica Corp (NASDAQ: ANGN) and Vifor Pharma shared results from the Phase 2 GUARD trial of Angion's ANG-3777 in cardiac surgery patients with cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI).
Oppenheimer Maintains Outperform on Angion Biomedica, Lowers Price Target to $8
10 Dec 21
News, Price Target, Analyst Ratings
Oppenheimer analyst Justin Kim maintains Angion Biomedica (NASDAQ:ANGN) with a Outperform and lowers the price target from $15 to $8.
Angion and Vifor Pharma Report Topline Results From Phase 2 GUARD Trial Of ANG-3777 In Cardiac Surgery-Associated Acute Kidney Injury
9 Dec 21
Biotech, News, FDA, General
Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion's ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at
Angion Biomedica Q3 EPS $(0.53) Up From $(1.19) YoY, Sales $1.50M
12 Nov 21
Earnings, News
Angion Biomedica (NASDAQ:ANGN) reported quarterly losses of $(0.53) per share. This is a 55.46 percent increase over losses of $(1.19) per share from the same period last year. The company reported $1.50 million in
HC Wainwright & Co. Maintains Buy on Angion Biomedica, Lowers Price Target to $50
9 Nov 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Angion Biomedica (NASDAQ:ANGN) with a Buy and lowers the price target from $100 to $50.
64 Biggest Movers From Yesterday
28 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
Mid-Afternoon Market Update: Nasdaq Surges Over 100 Points; Cortexyme Shares Plunge
27 Oct 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Toward the end of trading Wednesday, the Dow traded down 0.23% to 35,674.01 while the NASDAQ rose 0.81% to 15,358.79. The S&P also rose, gaining 0.14% to 4,581.2.
Mid-Day Market Update: Dow Falls Over 100 Points; Silicon Laboratories Shares Spike Higher
27 Oct 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Wednesday, the Dow traded down 0.30% to 35,648.39 while the NASDAQ rose 0.32% to 15,283.97. The S&P also fell, dropping 0.03% to 4,573.51.
44 Stocks Moving In Wednesday's Mid-Day Session
27 Oct 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers AgriFORCE Growing Systems, Ltd. (NASDAQ: AGRI) shares climbed 105.3% to $4.4350. AgriFORCE Growing Systems reported binding LOI to acquire a European agriculture/horticulture and agtech consulting firm for $29 million.
Stifel Maintains Buy on Angion Biomedica, Lowers Price Target to $15
27 Oct 21
News, Price Target, Analyst Ratings
Stifel analyst Annabel Samimy maintains Angion Biomedica (NASDAQ:ANGN) with a Buy and lowers the price target from $40 to $15.

Press releases

From Benzinga Pro
Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference
4 Jan 22
News, Health Care, Press Releases, General
-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE, N.Y., Jan. 04, 2022
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
10 Dec 21
Press Releases
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury
9 Dec 21
News, Analyst Ratings, Press Releases, General
-- Angion to host a conference call today at 4:30 p.m. EST UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced
Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study
5 Nov 21
News, Health Care, Press Releases
UNIONDALE, N.Y., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule
Angion to Participate in Upcoming Investment Conference
2 Nov 21
News, Press Releases
UNIONDALE, N.Y., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule
Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function
27 Oct 21
Press Releases
Phase-III trial did not demonstrate a statistically significant difference from placebo on the primary endpoint of estimated Glomerular Filtration Rate (eGFR) at 12 months in patients at risk for delayed graft function